Mr. Fiddler has been a member and the chairman of our board of directors since 2004. From 1981 to 2009 Mr. Fiddler was the founder, Chief Executive Officer and chairman of Wind River Systems, a software company, until it was acquired by Intel, a semiconductor company. Mr. Fiddler obtained a Master of Science from the University of Illinois.
Mr. Arbige has been a member of our board of directors since 2005. From 1990 to the present, Dr. Arbige has held a variety of positions at Genencor, a diversified biotechnology company, and is currently its Executive Vice President of Technology. Dr. Arbige obtained his Ph.D. in Microbial Physiology and Genetics from the University of New Hampshire.
Mr. Lese has been a member of our board of directors since 2008. He co-founded and since 2001 has served as a managing director of Braemar Energy Ventures, LP, a venture capital management company focused exclusively on investing in early to mid-stage energy technology companies in the United States and Canada. Mr. Lese holds a Bachelor of Arts in Physics and a Master of Science in Energy Sciences from New York University.
Mr. Clark is the Chief Executive Officer and head of North American Commercial Operations for Genentech, a member of the Roche Group. He joined Genentech in 2003 as Senior Vice President and General Manager, BioOncology, and in January 2006 was named Executive Vice President, Commercial Operations, and became a member of the Executive Committee. Prior to joining Genentech, Mr. Clark served as president of Novartis Canada, overseeing all of the company’s country operations. His previous board experience includes Vernalis and Dendreon, both publicly traded biopharmaceutical companies. Mr. Clark is also on the Board of the BIO Industry Association and an Advisor to the Institute of Life Sciences at Southampton University in the UK.
Ms. Mather is lead director at MGM Holdings Inc., a motion picture and television production and distribution company. She is also a member of the board at Google, where she serves as chair of the Audit Committee, and is a director at Netflix, Glu Mobile Inc., and MoneyGram International. Ms. Mather was formerly Chief Financial Officer at Pixar Studios and prior to that held senior roles at the Walt Disney Company.
Mr. Kovacs joined Solazyme's board in February 2013. Prior to that, he was a Strategic Advisor to the company, bringing a wealth of knowledge across multiple industries related to Solazyme's business. Mr. Kovacs began his career the Kelco Company, a San Diego-based specialty chemicals manufacturer and a Division of Merck & Co. Inc., as a laboratory chemist in 1967. After a series of domestic and international technical and business assignments, Mr. Kovacs was appointed President and CEO of the company in 1993, leading to the sale of Kelco to Monsanto in 1994. He was subsequently chosen to join the Monsanto Operating Council and to merge the NutraSweet Company with Kelco, forming an $800 million food ingredient firm, which became one of the largest industrial biotechnology companies, the NutraSweet Kelco Company. He served as President and CEO until his retirement in 1997 after 30 years of service.